论文部分内容阅读
美国Merck研究实验室发现了一种天然存在的可溶性flt-1受体,Merck公司计划把它用于病理性血管生成的治疗。Flt-1是一种血管内皮生长因子（VEGF）受体,在血管生成时,在增殖的内皮细胞上能天然表达flt-1,而血管生成过程是从现有的血管中芽生出新血管,连接形成全新的毛细血管。 在行经、胚胎发生和伤口愈合期间血管生成是个自然过程,但是实体瘤生长、类风湿性关节炎和视网膜黄斑变性则是依赖异常血管生成的一些疾病。阻断血管生成能为治疗上述疾病提供方法。例如,flt-1受体与黑素瘤、神经胶质瘤、乳头状癌、卵泡癌、脑膜瘤和卵巢肿瘤有关。VEGF对结肠直肠、胃、神经胶质、卵巢、乳腺、肺和甲状腺肿瘤等起正调节作用。
Merck Research Laboratories in the US discovered a naturally occurring soluble flt-1 receptor, and Merck plans to use it for the treatment of pathological angiogenesis. Flt-1, a vascular endothelial growth factor (VEGF) receptor, naturally expresses flt-1 on proliferating endothelial cells during angiogenesis, which is the process by which new blood vessels emerge from existing blood vessels, Connect to form a new capillary. Angiogenesis is a natural process during menstruation, embryogenesis and wound healing, but solid tumor growth, rheumatoid arthritis and retinal macular degeneration are a few diseases that depend on aberrant angiogenesis. Blocking angiogenesis can provide a cure for these diseases. For example, the flt-1 receptor is associated with melanoma, glioma, papillary carcinoma, follicular carcinoma, meningioma and ovarian tumors. VEGF plays a positive regulatory role in colorectal, gastric, glial, ovarian, breast, lung and thyroid tumors.